GLP-1 receptor agonists may reduce the likelihood of mortality and increase odds for transplant wait-listing for patients ...

GLP-1 drugs have been in the news a lot lately. Most recently, Serena Williams went public about taking GLP-1s as part of her weight loss journey. In a nutshell, GLP-1s are a trending topic—and one ...

Semaglutide is linked to significant weight loss and glucose levels in adults with schizophrenia, overweight/obesity, and ...

A large Cleveland Clinic study has found that people with obesity and type 2 diabetes who undergo weight-loss surgery live longer and face fewer serious health problems compared with those treated ...

The WHO added 20 new medicines to the EML, including GLP-1 RAs, 15 to the EMLc, and new indications for 7 existing medicines.

It's now preparing to submit a third weight loss drug to regulators for review. The growth of this healthcare niche looks to ...

Novo Nordisk’s Wegovy will be competing with Madrigal Pharmaceuticals’ Rezdiffra in the metabolic dysfunction-associated ...

Novo Nordisk announced that the European Medicines Agency (EMA) has approved an update to the label for Rybelsus (oral ...

WEIGHT loss jabs could be given to children as young as six to treat obesity or type 2, researchers suggest. But stomach problems were “significantly more common” among youngsters ...

GLP-1RAs were associated with lower risk for major adverse cardiovascular and cerebrovascular events in MGUS with type 2 diabetes.

Committee for Medicinal Products for Human Use (CHMP) approved an update to Novo Nordisk A/S‘ (NYSE:NVO) Rybelsus (oral ...

Results show that GLP-1s may address rheumatoid arthritis (RA) symptoms, independent of established weight loss and cardiac benefits, by reducing the systemic, chronic inflammation associated with RA.